Reuters reveals India unlikely to resume sizable COVID-19 vaccine exports until October

Reuters was first to report that India is unlikely to resume major exports of COVID-19 vaccines until at least October as it diverts shots for domestic use, a longer-than-expected delay set to worsen supply shortages for the global COVAX vaccine initiative. The news drew strong reaction from across the world and was confirmed by Serum Institute of India, the world’s largest vaccine maker and a key supplier to the COVAX initiative, when it announced late in the day that it hopes to be able to restart deliveries to COVAX and other countries by year end.

Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: AsiaEmerging MarketsGlobal
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Major Global Story
Sign up for email updates

Sign up for email updates